Lv61
1847 积分 2024-01-19 加入
Current Use of Physiologically‐Based Pharmacokinetic (PBPK) Modeling in New Medicinal Product Approvals at EMA: A Clinical Appraisal of Voclosporin in Lupus Nephritis
9天前
已完结
Gene Therapy for Phenylketonuria in Adults
14天前
已完结
Development of a minimal physiologically-based pharmacokinetic/pharmacodynamic model to characterize target cell depletion and cytokine release for T cell-redirecting bispecific agents in humans
1个月前
已完结
FDA-Industry Scientific Exchange on assessing quantitative systems pharmacology models in clinical drug development: a meeting report, summary of challenges/gaps, and future perspective
2个月前
已完结
Role of Data in Development and Application of Quantitative Systems Pharmacology Models
2个月前
已完结
Structural and practical identifiability analysis of partially observed dynamical models by exploiting the profile likelihood
2个月前
已完结
No Recipe for Quantitative Systems Pharmacology Model Validation, but a Balancing Act Between Risk and Cost
2个月前
已完结
Recommendations for a standardized publication protocol for a QSP model
2个月前
已完结
Prediction of pharmacokinetics and CNS effects of fentanyl and alfentanil in mice, rats and humans using cross-species PBPK-PD model and in vitro PK/PD parameters
3个月前
已完结
Development of a generic physiologically based pharmacokinetic model to predict clinical pharmacokinetics and assess drug-drug interaction risks for vcMMAE-based antibody-drug conjugates
4个月前
已完结
皖公网安备34019202002308
